|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Colorectal cancer and dysplasia in inflammatory bowel disease显示文摘Both ulcerative colitis and Crohn’s disease carry an increased risk of developing colorectal cancer. Established risk factors for cancer among patients with inflammatory bowel disease (IBD) include the younger age at diagnosis, greater extent and duration of disease, increased severity of inflammation, family history of colorectal cancer and coexisting primary sclerosing cholangitis. Recent evidence suggests that current medical therapies and surgical techniques for inflammatory bowel disease may be reducing the incidence of this complication. Nonetheless heightened vigilance and a careful, comprehensive approach to prevent or minimize the complications of invasive cancer are warranted in this unique cohort of patients. Current guidelines for the prevention and early detection of cancer in this high risk population are grounded in the concept of an inflammation-dysplasia- carcinoma sequence. A thorough understanding of the definition and natural history of dysplasia in IBD, as well as the challenges associated with detection and interpretation of dysplasia are fundamental to developing an effective strategy for surveillance and prevention, and understanding the limitations of the current approach to prevention. This article reviews the current consensus guidelines for screening and surveillance of cancer in IBD, as well as presenting the evidence and rationale for chemoprevention of cancer and a discussion of emerging technologies for the detection of dysplasia. | Timothy L Zisman David T Rubin | 2008 | World Journal of Gastroenterology2008，14，17： | 13 |
| 2 | Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease显示文摘There have been increasing concerns regarding the safety of perioperative anti-tumour necrosis factor (anti-TNF) α agents. We performed a literature review to evaluate the post-operative complications associated with perioperative anti-TNF use in patients with inflammatory bowel disease. A comprehensive review was performed with a literature search utilizing Pub Med, Cochrane, OVID and EMBASE databases according to published guidelines. To date, there are only data for infliximab. There are three published studies which have assessed post-operative complications with perioperative infliximab use in patients with Crohn' s disease (CD), four studies in ulcerative colitis (UC) patients, and one study on both CD and UC patients. Two out of the three studies in CD patients showed no increased post-operative complications associated with perioperative infliximab. Two out of four studies in UC patients also did not show an increase in post-operative complications, and the combined study with CD and UC patients did not show an increased risk as well. Studyresults could not be combined secondary to significant differences in study designs, patient population and definition of their endpoints. There appears to be a risk of post-operative complications associated with TNF therapy in some patients. Based on these data, careful patient selection and prospective data collection should be performed. | Tauseef Ali Laura Yun David T Rubin | 2012 | World Journal of Gastroenterology2012，18，3： | 2 |
| 3 | Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations显示文摘 | DAVID T RUBIN PAREKH NIMISHA | 2006 | Curr Treat Options Gastroenterol2006，9，： | 1 |
| 4 | Evolving role of endoscopy in inflammatory bowel disease:Going beyond diagnosis显示文摘Inflammatory bowel disease,encompassing Crohn’s disease(CD)and ulcerative colitis,are chronic immune-mediated inflammatory bowel diseases(IBD)that primarily affect the gastrointestinal tract with periods of activity and remission.Large body of evidence exist to strengthen the prognostic role of endoscopic evaluation for both disease activity and severity and it remains the gold standard for the assessment of mucosal healing.Mucosal healing has been associated with improved clinical outcomes with prolonged remission,decreased hospitalization,IBD-related surgeries and colorectal cancer risk.Therefore,endoscopic objectives in IBD have been incorporated as part of standard care.With the known increased risk of colorectal cancer in IBD,although prevention strategies continue to develop,regular surveillance for early detection of neoplasia continue to be paramount in IBD patients’care.It is thanks to evolving technology and visualization techniques that surveillance strategies are continuously advancing.Therapeutic endoscopic options in IBD have also been expanding,from surgery sparing therapies such as balloon dilation of fibrostenotic strictures in CD to endoscopic mucosal resection of neoplastic lesions.In this review article,we discuss the current evidence on the use of endoscopy as part of standard of care of IBD,its role in surveillance of neoplasia,and the role of interventional endoscopic therapies. | Paulina Núñez F Noa Krugliak Cleveland Rodrigo Quera David T Rubin | 2021 | World Journal of Gastroenterology2021，27，20： | 1 |
| 5 | Efficacy of various endoscopic modalities in detecting dysplasia in ulcerative colitis:A systematic review and network meta-analysis显示文摘BACKGROUND Longstanding ulcerative colitis(UC)is associated with an increased risk of colonic neoplasia.Various endoscopic modalities,such as chromoendoscopy(CE),narrow band imaging(NBI)and random biopsy have been introduced for surveillance,however,there exists a paucity of direct comparisons between them.We aimed to conduct a network meta-analysis of randomized controlled trials(RCTs)performed for surveillance of neoplasia in UC.AIM To provide a comparative evaluation of the efficacy of the above-mentioned various modalities.METHODS We searched MEDLINE/PubMed,Web of Science,Embase,Google Scholar and Cochrane Central Registry through May 2016 for RCTs evaluating the efficacy of endoscopic modalities for surveillance of neoplasia in UC.The primary outcomes of interest were dysplasia(low-or high-grade)detection rates per biopsy and per patient,and dysplasia numbers per patient.Studies were simultaneously analyzed using a random-effects network meta-analysis under the Bayesian framework to identify the modality with the highest dysplasia detection rate.The best ranking probability for the dysplasia detection rate was analyzed by surface under the cumulative ranking(SUCRA)technique.RESULTS Six prospective RCTs of a total 1038 patients were identified.We identified 4 different modalities;white light(WL)high definition(HD)or standard definition(SD),CE HD,and NBI HD.For dysplasia per biopsy,direct meta-analysis showed superiority of NBI HD over WL HD and CE HD over WL SD.Network meta-analysis demonstrated the rank order of best modality as NBI HD,CE HD,WL HD and WL SD with close SUCRA scores of the first two.For dysplasia per patient,direct meta-analyses showed equivocal results between each modality.Network meta-analysis demonstrated the rank order of best modality as WL HD,NBI HD,CE HD and WL SD with small differences of the SUCRA score among the first two.For dysplasia numbers per patient,direct meta-analysis showed superiority of CE HD over WL SD.Network meta-analysis demonstrated the rank order of best modality as WL HD,NBI HD,CE HD,and WL SD with small differences of the SUCRA score among the first three.CONCLUSION We demonstrated that there were small differences among WL HD,NBI HD,and CE HD,while WL SD was inferior,in detecting dysplasia in UC. | Bilal Gondal Haider Haider Yuga Komaki Fukiko Komaki Dejan Micic David T Rubin Atsushi Sakuraba | 2020 | World Journal of Gastrointestinal Endoscopy2020，12，5： | 1 |
| 6 | Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget显示文摘Inflammatory bowel disease(IBD),encompassing Crohn's disease and ulcerative colitis,is a chronic immune-mediated inflammatory disease that primarily affects the gastrointestinal tract and is characterized by periods of activity and remission.The inflammatory activity of the disease involving the colon and rectum increases the risk of colorectal cancer(CRC)over the years.Although prevention strategies are evolving,regular surveillance for early detection of neoplasia as a secondary prevention strategy is paramount in the care of IBD patients.In this review article,we discuss the current evidence of the risks of developing CRC and evaluate the best available strategies for screening and surveillance,as well as future opportunities for cancer prevention. | Paulina Núñez F Rodrigo Quera David T Rubin | 2022 | World Journal of Gastrointestinal Endoscopy2022，14，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员